ML28641 - Subcutaneous tocilizumab in rheumatoid arthritis

• Research type

  Research Study

• Full title

  Open-label, Phase IIIb study to evaluate the efficacy and safety of subcutaneous (SC) Tocilizumab monotherapy or combination therapy with methotrexate (MTX) or other non-biologic disease modifying anti-rheumatic drugs (DMARDs) in patients with severe Rheumatoid Arthritis (RA) who are being treated with an anti-tumour necrosis factor (anti-TNF) agent and that have not achieved an adequate response to treatment.

• IRAS ID

  133239

• Contact name

  John Isaacs

• Contact email

  John.Isaacs@newcastle.ac.uk

• Sponsor organisation

  Roche Products Ltd

• Eudract number

  2013-000054-22

• ISRCTN Number

  n/a

• REC name

  Yorkshire & The Humber - Leeds East Research Ethics Committee

• REC reference

  13/YH/0282

• Date of REC Opinion

  9 Sep 2013

• REC opinion

  Favourable Opinion